Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.31 |
| ▸ | PGR | P06401 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24109718 | 0.88 | TNF (0.33) | HTR2AHTR2CBPTFKDM4EMEN1 | |
| SCHEMBL24109707 | 0.86 | KDM4E (0.38) | HTR2AHTR2CBPTFKDM4EMEN1 | |
| SCHEMBL24109975 | 0.83 | FABP4 (0.39) | NR3C1HTR2AHTR2CKDM4EMEN1 | |
| SCHEMBL24110348 | 0.83 | HTR2C (0.37) | HTR2AHTR2C | |
| SCHEMBL24109730 | 0.82 | HTR2C (0.33) | HTR2AHTR2C | |
| SCHEMBL24110303 | 0.81 | NR3C1 (0.32) | NR3C1HTR2AHTR2C | |
| SCHEMBL30404792 | 0.80 | KDM4E (0.37) | HTR2AHTR2CKDM4EMEN1MAPT | |
| SCHEMBL24109714 | 0.80 | KDM4E (0.37) | HTR2AHTR2CKDM4EMEN1MAPT | |
| SCHEMBL24110285 | 0.77 | HTR2A (0.33) | HTR2AHTR2CTNF | |
| SCHEMBL24110335 | 0.76 | HTR2C (0.40) | NR3C1HTR2AHTR2CTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252692-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | NR3C1 1240/4885NTRK1 523/4885HTR2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.